JUNIPER: A Phase 2 Study to Evaluate the Safety, Biological Activity, and PK of ND-L02-s0201 in Subjects With IPF

NCT03538301 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

123

Enrollment

INDUSTRY

Sponsor class

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

DRUG: ND-L02-s0201 (Low Dose)
DRUG: ND-L02-s0201 (High Dose)
OTHER: Other: Placebo

Sponsor

Nitto Denko Corporation